Next 10 |
2024-05-10 12:57:54 ET Gainers: Novavax NVAX +106% . AEye LIDR +67% . ITeos Therapeutics ITOS +48% . Sensus Healthcare SRTS +35% . Inseego Corp INSG +32% . Sweetgreen SG +33% . Organogenesis Holdings ORGO +33% . Caredx CDNA +32...
2024-05-09 22:42:09 ET Revance Therapeutics Inc. (RVNC) Q1 2024 Results Earnings Conference Call May 9, 2024, 04:30 PM ET Company Participants Laurence Watts - Investor Relations, New Street IR Mark Foley - Chief Executive Officer Tobin Schilke - Chief Financial ...
2024-05-09 16:50:00 ET More on Revance Therapeutics Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain Revance Therapeutics Q1 2024 Earnings Preview Survey finds GLP-1 user...
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
2024-05-08 17:35:55 ET Major earnings expected after the bell on Thursday include: Unity Software ( U ) Main Street Capital Corporation ( MAIN ) Marathon Digital Holdings ( MARA ) Wheaton Precious Metals Corp. ( WPM ) Blink Charging Co. ( BLNK ) ...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...
2024-04-22 16:53:54 ET Gainers: Oportun Financial ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...
2024-04-16 10:47:43 ET More on AbbVie AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% AbbVie keeps Humira market share near 100% despite biosimilars: rep...
– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...
2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday. Revance Therapeutics posted a GAAP loss of 54 cents per s...
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...